Cardiology · 2002
Heart Protection Study (HPS)
MRC/BHF Heart Protection Study
Through the 1990s, most clinicians treated lipid-lowering as a matter of reaching a target LDL number. If a patient's LDL looked acceptable, the reasoning went, adding a statin offered little. The MRC/BHF Heart Protection Study was designed specifically to test that assumption, enrolling 20,536 adults whose cardiovascular risk was high for reasons beyond their cholesterol levels: prior heart disease, peripheral arterial disease, diabetes, or treated hypertension.
Randomization assigned participants to 40 mg simvastatin daily or matching placebo, with follow-up running to five years at collaborating centers across the United Kingdom. The primary results, published in the Lancet in July 2002, showed a 24% reduction in major vascular events in the statin group, encompassing coronary deaths, non-fatal myocardial infarction, stroke, and coronary or peripheral revascularization. All-cause mortality fell by 13% in the simvastatin arm.
The subgroup most important to practicing clinicians was the one with baseline LDL below 3.0 mmol/L. That group gained roughly the same relative benefit as those starting above the threshold, which meant the trial's logic did not depend on the entry cholesterol. Risk level determined the gain, not starting lipid value. This single finding made the statin debate less about cholesterol targets and more about identifying high-risk patients.
Clinicians had routinely withheld statins from diabetic patients without overt coronary disease, from stroke survivors, and from those with peripheral arterial disease on the grounds that LDL was not clearly elevated. HPS enrolled all three groups in meaningful numbers and showed consistent benefit across each. Women and patients over 70 also showed proportionate reduction in events, addressing two populations that earlier statin trials had enrolled sparsely.
The practical consequences showed up in prescribing data within a few years. National formularies and guideline committees in the United Kingdom, Europe, and North America updated recommendations to extend statin eligibility based on total cardiovascular risk rather than lipid thresholds alone. The 2002 Lancet paper's table of subgroup results became a standard reference point in those deliberations, cited in documents that governed statin access for millions of patients.
Key People
- Rory Collins — Lead investigator, MRC Clinical Trial Service Unit, Oxford
- Jane Armitage — Co-investigator; oversaw trial coordination
- Richard Peto — Oxford statistician; co-designed the meta-analytic approach
Lancet. 2002;360(9326):7-22.
Related landmarks
- 2003 · Primary PCI versus thrombolysis for acute STEMI (Keeley meta-analysis of 23 trials) (Cardiology)
- 2000 · HOPE (Heart Outcomes Prevention Evaluation) (Cardiology)
- 1995 · WOSCOPS (West of Scotland Coronary Prevention Study) (Cardiology)
- 2009 · RE-LY (Dabigatran versus warfarin in atrial fibrillation) (Cardiology)